Nerviano Medical Sciences

The largest pharmaceutical R&D facility in Italy and one of the largest oncology-focused, integrated discovery and development companies in Europe.
Vinaora Nivo SliderVinaora Nivo SliderVinaora Nivo SliderVinaora Nivo SliderVinaora Nivo SliderVinaora Nivo SliderVinaora Nivo SliderVinaora Nivo SliderVinaora Nivo SliderVinaora Nivo SliderVinaora Nivo Slider

Latest News

Two young researchers of Nerviano Medical Sciences winners of the award “Premio Società Italiana di Farmacologia- Farmindustria per Ricerche Farmacologiche” 2014 September 17, 2014 - Nerviano, Italy. Congratulations to Daniela Asa and Fabio Gasparri, scientists at Nerviano Medical Sciences in the Biotechnology and Cell Biology Departments, respectively, for winning the prize of the “Società Italiana di Farmacologia (SIF)- Farmindustria per Ricerche Farmacologiche” 2014.The prize, intended to reinforce the scientific research and partnering between... Read more
Ignyta and Nerviano Announce License Agreement for Two First-in-Class Kinase Inhibitors August 4, 2014 - San Diego, CA, USA & Nerviano, Italy --(BUSINESS WIRE)-- Ignyta, Inc. (Nasdaq: RXDX), an oncology precision medicine biotechnology company, and Nerviano Medical Sciences, S.r.l., a leading oncology discovery organization, today announced that they have signed a license agreement that grants Ignyta exclusive global development and commercialization rights to two new drug... Read more
Cellectis and Accelera (Nerviano Medical Sciences Group) sign an agreement to complete preclinical studies of Cellectis lead product candidate UCART19 June 5, 2014 – Milan (Italy) and Paris (France) – Cellectis (Alternext: ALCLS.PA), a leader of allogeneic CAR T-cell therapies, and Accelera, the preclinical CRO (Contract Research Organisation) within the Nerviano Medical Sciences Group, recently signed an agreement to complete the preclinical studies of Cellectis’ advanced product candidate, UCART19. Engineered allogeneic CD19 T-cells... Read more


Nerviano Medical SciencesWe fight cancer. Our mission is to identify innovative agents for clinical development in areas of unmet



Nerviano Medical SciencesCLIOSS operates as your partner in the clinical development and life-cycle management



AcceleraAccelera is committed to predicting and managing potential toxic, pharmacokinetic



NerpharmaNerPharMa is a leading player in high-containment contract